JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258924

Human IP6K2 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

IP6K2 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.

View Alternative Names

ATP 1D myo inositol hexakisphosphate phosphotransferase, IHPK 2, IP6K2_HUMAN, Inositol hexakisphosphate kinase 2, InsP6 kinase 2, KIAA0263, OTTHUMP00000164824, P(i)-uptake stimulator, Pi uptake stimulator, PiUS

1 Images
Sanger Sequencing - Human IP6K2 knockout HeLa cell lysate (AB258924)
  • Sanger seq

Unknown

Sanger Sequencing - Human IP6K2 knockout HeLa cell lysate (AB258924)

Homozygous : 1 bp insertion in exon2

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258924-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human IP6K2 knockout HeLa cell lysate", "number":"AB258924-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258924-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IP6K2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The IP6K2 protein also known as inositol hexakisphosphate kinase 2 functions mechanically as an enzyme that converts inositol hexakisphosphate (IP6) into diphosphoinositol pentakisphosphate (IP7). It has a molecular mass of about 55 kDa. This kinase is widely expressed in various tissues with significant levels found in the brain and testes. IP6K2 activity plays a role in cellular energy homeostasis and signaling.
Biological function summary

IP6K2 influences several cellular processes including apoptosis and cell cycle regulation. It operates as a part of protein complexes that mediate the synthesis of inositol pyrophosphates which are important secondary messengers in cells. Through these roles IP6K2 helps regulate physiological functions such as insulin signaling and energy balance. Its interactions with various binding partners also enable it to influence cell survival and growth parameters.

Pathways

IP6K2 is actively involved in the inositol phosphate metabolism and apoptosis pathways. Inositol phosphate metabolism involves a range of signaling molecules where IP6K2 contributes to the generation of key signaling lipids. It works in conjunction with other kinases such as IP6K1 and phosphatidylinositol 3-kinase (PI3K) facilitating complex cellular activities. Through these pathways IP6K2 modulates processes that are essential for maintaining cell viability and proper cellular responses to external stimuli.

Dysregulation of IP6K2 has associations with several conditions including cancer and metabolic disorders. Altered IP6K2 function can influence cancer development by affecting apoptotic pathways where it interacts with key proteins such as p53 to regulate cell death. In metabolic disorders the kinase's role in insulin signaling connects it to metabolic issues like type 2 diabetes as its involvement in signal transduction impacts glucose homeostasis and insulin sensitivity.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com